Biotech Startups

ZeaKal develops plant trait technologies that improve crop photosynthetic capacity to increase nutritional density, carbon capture, and resource efficiency, serving agricultural producers and energy companies seeking sustainable food and fuel production.

1 investor

Zehna Therapeutics is an early-stage biotech company developing non-bactericidal small-molecule inhibitors of gut microbial enzymes, with lead compounds targeting CutC lyase to lower TMAO levels. Its work focuses on treating cardiometabolic and chronic diseases, with chronic kidney disease as its lead indication.

1 investor

ZEJULA is a prescription oral medicine (niraparib) used as maintenance treatment in adults with advanced ovarian, fallopian tube, or primary peritoneal cancer that has responded to platinum-based chemotherapy, including cancers with abnormal BRCA genes or homologous recombination deficiency. It is a pharmaceutical product in the oncology category.

1 investor

ZEMDRI (plazomicin) is an aminoglycoside antibiotic injection indicated for adults with complicated urinary tract infections, including pyelonephritis, caused by certain susceptible microorganisms. The product is a prescription pharmaceutical marketed by Cipla Therapeutics.

1 investor

Zene provides genetic testing and genome analysis services, along with a genome data analytics platform for health insights. The company serves individuals seeking personalized health information based on genomic data.

1 investor

ZenQMS provides a cloud-based electronic quality management system (eQMS) for life sciences and GxP-regulated organizations, with document control, audit, risk assessment, and validation capabilities. It includes validation and re-qualification documentation as part of a fixed implementation fee to support FDA compliance efforts.

1 investor

Zentek is a deep-science company developing three independent platforms: nuclear-grade graphite, graphene coatings, and aptamer biosciences. The company operates on a client-funded contract research organization (CRO) model, developing solutions for clients while retaining intellectual property ownership.

1 investor

1 investor

Zepto develops a targeted liquid biopsy platform for infectious disease diagnostics, offering plasma-based molecular testing through its CLIA reference laboratory and an integrated sample-to-result platform for use in hospital laboratories. It also provides analytical performance and reference testing support to help diagnostics obtain FDA clearance.

1 investor

Zerion is a pharmaceutical development company that uses its Dispersome formulation technology to improve the solubility and therapeutic performance of poorly soluble drugs. Spun out of the University of Copenhagen in 2019, it builds an internal drug pipeline while partnering with pharmaceutical companies to solve drug solubility challenges.

1 investor

1 investor

Zest Bio uses engineered microorganisms to convert low-value industrial fruit and vegetable processing waste — such as citrus peels, sugar beet pulp, potato peels, and grape pomace — into higher-value products. The company applies synthetic biology and green chemistry to agricultural byproducts.

1 investor

Zetagen is a biotechnology company focused on bone-related disease, developing small-molecule therapeutics and approaches targeting bone tumor progression, stem cell activity to promote bone formation, and cancers such as Ewing's sarcoma.

1 investor

Zeteo Tech develops mass spectrometry and detection technologies for biomedical, defense, and security applications, including bioaerosol detection and breath analysis. The company works across areas such as TB and breath diagnostics and defense/security programs.

1 investor

ZEV Biotech develops IRIS®, an integrated molecular diagnostics platform combining reagents, hardware, and software that can test multiple genomic biomarkers across small batches of patient samples. It targets laboratories, research institutions, and hospitals, aiming to make molecular diagnostics accessible in decentralized settings, with a focus on Latin America.

1 investor

Zevra Therapeutics develops and commercializes rare disease treatments, including therapies for Niemann-Pick disease type C and urea cycle disorders. The company serves patients with inherited metabolic and genetic disorders through FDA-approved pharmaceutical products.

1 investor

Zeyton produces hydroxytyrosol-rich extracts from olives using a patented mechanical process without chemical transformations or solvents. The company supplies these natural polyphenol-based ingredients to food manufacturers for fortification of olive oils, margarines, dairy, and other consumer products.

1 investor

The site publishes Chinese-language news and commentary on biomedical research, covering topics such as National Natural Science Foundation of China grant programs, academic misconduct cases, journal retractions, and summaries of recent studies in genetics and oncology. It appears to function as a content/media outlet for the scientific research community.

1 investor

Zhongze Therapeutics is a drug discovery company developing innovative agents for psychiatric disorders, with a pipeline targeting unmet clinical needs in schizophrenia, depression, bipolar disorder, and autism through multi-target, multi-mechanism approaches. It focuses on the research, development, and commercialization of novel treatments in the central nervous system and psychiatric therapeutics space.

1 investor

Zilia develops a medical imaging platform that measures biomarkers in the eye to enable early detection of preventable blindness, including glaucoma and diabetic retinopathy. The company leverages spectroscopy and artificial intelligence to provide non-invasive assessment of ocular metabolic activity.

1 investor

ZimVie provides dental implant solutions, including full-arch immediate load implant systems, designed to improve patient smiles, function, and confidence. The company serves dental professionals and patients in Canada.

1 investor

Ziopharm Oncology is a preclinical-stage biopharmaceutical company developing orally administered small-molecule drugs for obesity and metabolic disorders, particularly fatty liver disease, using a non-hormonal mechanism distinct from existing hormone-based treatments. The company previously operated as an oncology-focused cell therapy developer but has transitioned its focus to metabolic disease.

1 investor

ZIÖRA develops fertility technologies for IVF and IUI clinics, including FERTILUX, a patented ex-vivo sperm activation treatment that enhances sperm function to improve embryo quality and pregnancy outcomes in assisted reproductive technology. The company is building a pipeline of reproductive technologies aimed at improving gamete quality and clinic efficiency in the global fertility-care market.</parameter> <parameter name="founders">[]

1 investor

Ziwig develops a saliva-based diagnostic test for endometriosis that analyzes salivary miRNA using next-generation sequencing and AI to identify disease-characteristic profiles. Its CE-marked in vitro diagnostic device is intended for professional medical use.

1 investor